These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82 related articles for article (PubMed ID: 2588915)
1. National registry of cervical cytologic diagnoses in The Netherlands. Vooijs GP; Casparie-van Velsen IA; Peters FA; Beck HL Acta Cytol; 1989; 33(6):825-30. PubMed ID: 2588915 [TBL] [Abstract][Full Text] [Related]
2. Cellular composition of cervical smears in relation to the day of the menstrual cycle and the method of contraception. Vooijs GP; van der Graaf Y; Elias AG Acta Cytol; 1987; 31(4):417-26. PubMed ID: 3604536 [TBL] [Abstract][Full Text] [Related]
3. [Analysis of the intralaboratory diagnostic variability in the Imola cervical screening program]. Fabbris E; Bucchi L; Folicaldi S; Amadori A; Ghidoni D; Medri M; Bondi A Pathologica; 1998 Apr; 90(2):127-32. PubMed ID: 9619055 [TBL] [Abstract][Full Text] [Related]
4. [Less pap-2 results ('minor abnormalities') in the population screening for cervical cancer since the introduction of new guidelines in 1996]. Bos AB; van Ballegooijen M; van den Akker-van Marle ME; Habbema JD Ned Tijdschr Geneeskd; 2002 Aug; 146(34):1586-90. PubMed ID: 12224483 [TBL] [Abstract][Full Text] [Related]
5. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. Andrae B; Kemetli L; Sparén P; Silfverdal L; Strander B; Ryd W; Dillner J; Törnberg S J Natl Cancer Inst; 2008 May; 100(9):622-9. PubMed ID: 18445828 [TBL] [Abstract][Full Text] [Related]
6. The NCI All Ireland Cancer Conference. Johnston PG; Daly PA; Liu E Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862 [TBL] [Abstract][Full Text] [Related]
7. Cervical specimens collected in liquid buffer are suitable for both cytologic screening and ancillary human papillomavirus testing. Sherman ME; Schiffman MH; Lorincz AT; Herrero R; Hutchinson ML; Bratti C; Zahniser D; Morales J; Hildesheim A; Helgesen K; Kelly D; Alfaro M; Mena F; Balmaceda I; Mango L; Greenberg M Cancer; 1997 Apr; 81(2):89-97. PubMed ID: 9126136 [TBL] [Abstract][Full Text] [Related]
8. High-grade cervical abnormalities and screening intervals in New South Wales, Australia. Schindeler S; Morrell S; Zuo Y; Baker D J Med Screen; 2008; 15(1):36-43. PubMed ID: 18416954 [TBL] [Abstract][Full Text] [Related]
9. Cervical cancer screening programs: summary of the 1982. Canadian task force report. Can Med Assoc J; 1982 Oct; 127(7):581-9. PubMed ID: 7127225 [TBL] [Abstract][Full Text] [Related]
11. Results of the clinical evaluation of atypical glandular cells of undetermined significance (AGCUS) detected on cervical cytology screening. Kennedy AW; Salmieri SS; Wirth SL; Biscotti CV; Tuason LJ; Travarca MJ Gynecol Oncol; 1996 Oct; 63(1):14-8. PubMed ID: 8898161 [TBL] [Abstract][Full Text] [Related]
12. Cytologic and histologic findings in women using an IUD. Risse EK; Beerthuizen RJ; Vooijs GP Obstet Gynecol; 1981 Nov; 58(5):569-73. PubMed ID: 7301231 [TBL] [Abstract][Full Text] [Related]
13. Cervical cancer screening and management practices among providers in the National Breast and Cervical Cancer Early Detection Program (NBCCEDP). Saraiya M; Irwin KL; Carlin L; Chen X; Jain N; Benard V; Montano DE Cancer; 2007 Sep; 110(5):1024-32. PubMed ID: 17628488 [TBL] [Abstract][Full Text] [Related]
14. Cervical cancer screening program of Paraná: cost-effective model in a developing country. Bleggi Torres LF; Werner B; Totsugui J; Collaço LM; Araújo SR; Huçulak M; Boza EJ; Fischer RM; De Laat L; Sobbania LC; Raggio A Diagn Cytopathol; 2003 Jul; 29(1):49-54. PubMed ID: 12827718 [TBL] [Abstract][Full Text] [Related]
15. Monitoring a national cancer prevention program: successful changes in cervical cancer screening in the Netherlands. Rebolj M; van Ballegooijen M; Berkers LM; Habbema D Int J Cancer; 2007 Feb; 120(4):806-12. PubMed ID: 17131311 [TBL] [Abstract][Full Text] [Related]
16. Classification of cervical smears with discordance between the cytologic and/or histologic ratings. Willocx F; de Somer ML; Van Roy J Acta Cytol; 1987; 31(6):883-6. PubMed ID: 3425149 [TBL] [Abstract][Full Text] [Related]
17. Impact of the Walton report on cervical cancer screening programs in Canada. Kassirer E Can Med Assoc J; 1980 Feb; 122(4):417-23. PubMed ID: 7370844 [TBL] [Abstract][Full Text] [Related]
18. [Are analyses of cytological cervix smears from young women more harmful than beneficial?]. Skjeldestad FE; Hagen B; Hagmar B; Iversen OE; Juvkam KH; Steen R; Thoresen S; Hareide B Tidsskr Nor Laegeforen; 2007 Jun; 127(13):1782-5. PubMed ID: 17599128 [TBL] [Abstract][Full Text] [Related]
19. European guidelines for quality assurance in cervical cancer screening: recommendations for cytology laboratories. Wiener HG; Klinkhamer P; Schenck U; Arbyn M; Bulten J; Bergeron C; Herbert A Cytopathology; 2007 Apr; 18(2):67-78. PubMed ID: 17397490 [TBL] [Abstract][Full Text] [Related]
20. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1. Jordan J; Arbyn M; Martin-Hirsch P; Schenck U; Baldauf JJ; Da Silva D; Anttila A; Nieminen P; Prendiville W Cytopathology; 2008 Dec; 19(6):342-54. PubMed ID: 19040546 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]